Newsroom
Announcements, conference presence, and press coverage. For peer-reviewed methodology, see Publications.
Press release · Jul 09, 2026
Pentara presents five original Alzheimer's research studies at AAIC 2026
Five studies at the Alzheimer's Association International Conference in London, July 12–15, spanning the durability of anti-amyloid therapies, efficacy in the presence of comorbidities, representation in trial populations, biomarker cutoffs, and endpoint selection for pre-symptomatic trials. “The work we're presenting at AAIC is focused on practical statistical solutions that influence how clinical trials are designed, how results are interpreted, and ultimately how quickly promising therapies can reach patients,” said CEO Suzanne Hendrix, Ph.D.
10 items
Sorted newest first
-
Aug 13, 2026
Company newsView →Bio-Hermes biomarker analysis published in Alzheimer's & Dementia
Pentara biostatisticians Josh Christensen and Jessie Nicodemus-Johnson report on biomarkers in participants with clinical signs of MCI or mild AD but no amyloid deposits on PET, in collaboration with the Global Alzheimer's Platform Foundation, Emory University School of Medicine, and IXICO.
-
Aug 04, 2026
Company newsView →Landmark framework paper on self-administered digital cognitive assessments
A scoping review in Alzheimer's & Dementia, co-authored by CEO Suzanne Hendrix with an international group of experts, identifies 79 self-administered digital cognitive assessments and sets out a framework for validating them in unfiltered primary-care populations against biological anchors.
-
Jul 12, 2026
ConferenceView →AAIC 2026, London: five studies and Booth #100
July 12–15. Presenters included Suzanne Hendrix, Ph.D. on continued versus time-limited benefit of anti-amyloid monoclonal antibodies; Sam Dickson, Ph.D. on population-specific biomarker cutoffs; Garrett Duncan on treatment benefit in comorbid populations (poster 0108); and Caleb Dayley, M.S. on continuous endpoints versus time-to-event analysis in pre-symptomatic trials.
-
Jul 09, 2026
Press releaseRead →Pentara to present five original Alzheimer's research studies at AAIC 2026
Announcement of the company's AAIC program, covering anti-amyloid durability, biomarker selection, trial representation, and study design, with a CEO comment on statistical work that shortens the path from trial to patient.
-
Mar 17, 2026
ConferenceView →AD/PD 2026, Copenhagen: two ePosters on measurement and approvals
Sam Johnson and Abe Durrant presented ePoster #585, on statistical evaluation of the CDR-GS for more accurate outcome assessment, and ePoster #1487, a roadmap for navigating accelerated approvals in Alzheimer's drug development.
-
Jan 07, 2026
Media mentionRead →Science cites Pentara analysis in reporting on clinical trial data integrity
Suzanne Hendrix discusses proprietary analyses that flagged sites enrolling participants unlikely to have Alzheimer's disease, and cases of a single blood sample submitted for several participants, the kind of signal our fraud detection work is built to surface.
-
Dec 01, 2025
ConferenceView →CTAD 2025, San Diego: ten sessions including a late-breaking presentation with Eisai
December 1–4. Eight posters across Clinical Trials: Methodology and Clinical Trials: Results, plus the late-breaking session “Estimating the 10-Year Time-Savings Benefits of Lecanemab Treatment,” presented in collaboration with Eisai US.
-
Jul 30, 2025
Press releaseRead →NetraMark and Pentara partner on AI-driven detection of anomalous site and participant behavior
A co-branded site intelligence tool combining information-theoretic variability, singleton occurrence frequencies, and co-association penalties into a participant-level Paradox Risk score for assessing site-level trial integrity.
-
Jul 28, 2025
ConferenceView →AAIC 2025, Toronto: joint biomarker poster with ProMIS Neurosciences
Statistician Garrett Duncan co-presented “Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease” (poster 103841) with ProMIS Neurosciences' Chief Development Officer.
-
Apr 02, 2025
Media mentionRead →NeurologyLive covers Pentara-led analysis of pTau217 and pTau181 against trial endpoints
Reporting on AD/PD 2025 work led by Craig Mallinckrodt, Ph.D., examining patient-level and group-level correlations between plasma biomarkers and clinical outcomes across the ENGAGE, EMERGE, TRAILBLAZER, and Clarity AD trials.
Upcoming conferences
-
Nov 16–19, 2026
CTAD 2026, Boston, USA
Pentara will be attending. Session details are coming soon.
Conference website → (opens in a new tab) · Arrange a meeting
Recently presented
- AAIC 2026London · 5 studies
- AD/PD 2026Copenhagen · 2 ePosters
- CTAD 2025San Diego · 10 sessions
Media inquiries
For interviews, statistical commentary, or background on trial design and regulatory strategy, contact our press office. We respond to journalist deadlines the same day where we can.
1-801-485-9920
Downloads, boilerplate, and bios
Everything needed to write about Pentara accurately. For photography, additional formats, or an interview, contact the press office above.
Logo files
Primary logo
Horizontal wordmark with pentagon cluster and ®. The default for light backgrounds.
PNG · 1081×407
Download →
Pentagon icon mark
Icon only, carrying the superscript ™. Use where the wordmark cannot sit.
PNG · 609×462
Download →Usage rules
- Always reproduce from these approved files. Never redraw, recolor, stretch, rotate, crop, or add shadows, outlines, or containing boxes.
- Keep clear space equal to the height of the ‘P’ on all sides.
- Minimum size: full logo 115px / 1 in wide; icon mark 48px / 0.5 in.
- Use on white or light neutral backgrounds. On a saturated background, place the logo in a white container. Do not create a knockout version.
Boilerplate
Short (50 words)
Pentara® is an independent biostatistics and data science consultancy for clinical research. Founded in 2001 and based in Millcreek, Utah, the company provides study design, biostatistics, data management, statistical programming, medical writing, and regulatory support to pharmaceutical and biotechnology sponsors worldwide.
Long (110 words)
Pentara® is an independent biostatistics and data science consultancy serving pharmaceutical and biotechnology sponsors, CROs, and research organizations worldwide. Founded in 2001 and led by CEO Suzanne Hendrix, PhD, since 2008, the company supports every phase of clinical development: study design, biostatistics, data management, statistical programming, medical writing, and regulatory submission, with deep specialization in neurodegenerative disease. Independence is structural: self-funded research keeps the statistical advice free of commercial pressure. The team has published more than 200 peer-reviewed papers advancing trial methodology, and presents regularly at AAIC, CTAD, and AD/PD. Headquarters are in Millcreek, Utah.
Executive bios
-
Suzanne Hendrix, PhD
Chief Executive Officer
PhD in mathematics from Boston University and more than 30 years as a clinical trials statistician across CROs and pharmaceutical companies. CEO since 2008, focused on trials in degenerative disease, especially Alzheimer's. Author or co-author of over 150 peer-reviewed publications and a lead contributor to ADCOMS, a composite cognitive score for mild cognitive impairment.
-
Samuel Dickson, PhD
Sr. VP of Statistics
PhD in statistics and bioinformatics, working in clinical trials since 2003 on study design and analysis for Alzheimer's, Parkinson's, and ALS. Specializes in identifying outcomes able to detect treatment effects in heterogeneous progressive disease, and in phase 2/3 design including group sequential, sample size re-estimation, and Bayesian adaptive studies.
-
Jessie Nicodemus-Johnson, PhD
Senior Vice President of Biostatistics
More than 15 years in statistics, study design, and integrative physiology, leading trial design, CDISC dataset generation, and post-hoc outcome analysis. PhD in Molecular and Integrative Physiology from the University of Illinois Urbana-Champaign, followed by a postdoctoral fellowship in Human Genetics at the University of Chicago.
Pentara® and the Pentara pentagon mark are trademarks of Pentara Corporation. © 2026 Pentara Corporation. All rights reserved.